Valuation: Theralase Technologies Inc.

Market Cap 6.05Cr 4.33Cr 3.87Cr 3.55Cr 3.23Cr 410.21Cr 6.18Cr 42Cr 17Cr 216.52Cr 16Cr 16Cr 683.88Cr P/E 2026 *
-19.5x
P/E 2027 * 9.75x
Enterprise Value 6.05Cr 4.33Cr 3.87Cr 3.55Cr 3.23Cr 410.21Cr 6.18Cr 42Cr 17Cr 216.52Cr 16Cr 16Cr 683.88Cr EV / Sales 2026 *
77x
EV / Sales 2027 * 1.79x
Free-Float
79.6%
Yield 2026 *
-
Yield 2027 * -
1 day+8.33%
1 week-2.50%
Current month+8.33%
1 month+11.43%
3 months-31.58%
6 months-36.07%
Current year+18.18%
1 week 0.18
Extreme 0.175
0.2
1 month 0.18
Extreme 0.175
0.25
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Option

Director

3,360 0.0011%
27/08/26 Buy

Chief Executive Officer

42,000 0.0142%
24/08/26 Option

Chief Financial Officer

29,000 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-2.50%-7.14%0.00% 4.33Cr
-2.06%-0.33%+20.31%+52.52% 25TCr
-1.83%-2.15%+5.85%+18.13% 16TCr
+1.12%-3.27%-18.23%+57.21% 15TCr
+5.57%-2.76%-56.00%-15.61% 6.42TCr
+1.19%+2.62%-10.64%-8.42% 5.41TCr
+1.36%+2.98%+13.11%+42.32% 5.38TCr
-1.90%-3.51%+5.43%+61.66% 4.97TCr
-1.65%-2.26%+17.51%+64.63% 4.85TCr
-2.85%-1.41%+28.58%+83.18% 4.42TCr
Average +0.73%-2.41%-0.12%+35.56% 8.79TCr
Weighted average by Cap. -0.51%-1.28%+2.53%+40.43%

Financials

2026 *2027 *
Net sales 8L 6L 5L 5L 4L 5.33Cr 8L 55.05L 22.19L 2.81Cr 21.11L 20.66L 8.88Cr 3.39Cr 2.43Cr 2.17Cr 1.99Cr 1.81Cr 229.61Cr 3.46Cr 24Cr 9.57Cr 121.19Cr 9.1Cr 8.91Cr 382.78Cr
Net income -41.24L -29.51L -26.35L -24.18L -22L -28Cr -42.06L -2.89Cr -1.16Cr -15Cr -1.11Cr -1.08Cr -47Cr 69.01L 49.39L 44.09L 40.46L 36.81L 47Cr 70.39L 4.83Cr 1.95Cr 25Cr 1.85Cr 1.81Cr 78Cr
Net Debt - -
Projected Income Statement - Annual - Theralase Technologies Inc.
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
02/26/02 CA$0.1950 +8.33% 1,285
30/26/30 CA$0.1800 -10.00% 1,39,043
29/26/29 CA$0.2000 0.00% 23,500
28/26/28 CA$0.2000 0.00% 39,890
27/26/27 CA$0.2000 0.00% 1,13,762
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1950CAD
Average target price
0.7000CAD
Spread / Average Target
+258.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Theralase Technologies Inc.